Latest News
Issue of Equity on Exercise of Warrants
22 October 2020
London, New York, 22 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and...
Exercise of options, Issue of Equity PDMR Dealing and Total Voting Rights
21 October 2020
London, New York, 21 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and...
Issue of Equity on Exercise of Warrants
20 October 2020
London, New York, 20 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and...
Result of General Meeting
02 October 2020
At the General Meeting of the Company held at 11.00 a.m. on 2 October 2020, both of the resolutions were duly passed.
The anticipated timetable for the demerger of Accustem Sciences Limited (to be re-registered as Accustem Sciences Plc) is as...
Interim Results for the Six Months Ended 30 June 2020
30 September 2020
Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report
25 September 2020
Notable news
Video: Eyeing phase II clinical trial in HCC patients with milciclib
Dr. Kunwar Shailubhai talks to Tip TV about Tiziana receiving approval to start Phase IIa trials to test its leading compound milciclib, a CDK inhibitor as a treatment for hepatocellular carcinoma (HCC).